ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it will present a poster at The Liver Meeting® 2016 held by the American Association for the Study of Liver Diseases (AASLD), taking place November 11-15, 2016, in Boston.
The poster, titled, “Pharmacokinetics, Safety and Antiviral Activity of CMX157, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects,” will provide an overview of recent clinical data supporting CMX157, the company’s drug in development for hepatitis B virus (HBV).
Conference Details:
| Event: | The Liver Meeting 2016 |
| Date: | Monday, November 14, 2016 |
| Session: | Poster Session IV, “Hepatitis B: Treatment” |
| Poster #: | 1886 |
| Location: | John B. Haynes Veterans Memorial Convention Center; Boston |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action: CMX157, a highly potent analog of the successful antiviral drug tenofovir currently in a Phase 2a clinical trial in HBV patients; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing FV-100, an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a Phase 3 clinical trial. In addition to direct antiviral activity, FV-100 previously demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. For more information visit www.contravir.com.